{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:37:35Z","timestamp":1793353055848,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003382","name":"Core Research for Evolutional Science and Technology","doi-asserted-by":"publisher","award":["JPMJCR22N1"],"award-info":[{"award-number":["JPMJCR22N1"]}],"id":[{"id":"10.13039\/501100003382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23H03492"],"award-info":[{"award-number":["23H03492"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Next Cross-ministerial Strategic Innovation Promotion Program (SIP) on \"Integrated Health Care System\"","award":["JPJ012425"],"award-info":[{"award-number":["JPJ012425"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-91187-6","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T12:39:16Z","timestamp":1740400756000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Natural language processing of electronic medical records identifies cardioprotective agents for anthracycline induced cardiotoxicity"],"prefix":"10.1038","volume":"15","author":[{"given":"Yoshimasa","family":"Kawazoe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiminori","family":"Shimamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohisa","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuntaro","family":"Yada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Wakamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shungo","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Aramaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"91187_CR1","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn, T. T. & Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673\u2013683 (2004).","journal-title":"Nat. Rev. Drug Discov"},{"key":"91187_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom, S. et al. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov. 18, 41\u201358 (2019).","journal-title":"Nat. Rev. Drug Discov"},{"key":"91187_CR3","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/cpt.1769","volume":"107","author":"H Xu","year":"2020","unstructured":"Xu, H., Li, J., Jiang, X. & Chen, Q. Electronic health records for drug repurposing: current status, challenges, and future directions. Clin. Pharmacol. Ther. 107, 712\u2013714 (2020).","journal-title":"Clin. Pharmacol. Ther."},{"key":"91187_CR4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/clpt.2013.1","volume":"93","author":"MR Hurle","year":"2013","unstructured":"Hurle, M. R. et al. Computational drug repositioning: from data to therapeutics. Clin. Pharmacol. Ther. 93, 335\u2013341 (2013).","journal-title":"Clin. Pharmacol. Ther."},{"key":"91187_CR5","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1136\/amiajnl-2014-002649","volume":"22","author":"H Xu","year":"2015","unstructured":"Xu, H. et al. Validating drug repurposing signals using electronic health records: a case study of Metformin associated with reduced cancer mortality. J. Am. Med. Inf. Assoc. 22, 179\u2013191 (2015).","journal-title":"J. Am. Med. Inf. Assoc."},{"key":"91187_CR6","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/cpt.2454","volume":"111","author":"AL Kraus","year":"2022","unstructured":"Kraus, A. L. et al. Real-world data of Palbociclib in combination with endocrine therapy for the treatment of metastatic breast cancer in men. Clin. Pharmacol. Ther. 111, 302\u2013309 (2022).","journal-title":"Clin. Pharmacol. Ther."},{"key":"91187_CR7","doi-asserted-by":"publisher","first-page":"104674","DOI":"10.1016\/j.ebiom.2023.104674","volume":"94","author":"MM Shuey","year":"2023","unstructured":"Shuey, M. M. et al. A genetically supported drug repurposing pipeline for diabetes treatment using electronic health records. EBioMedicine 94, 104674 (2023).","journal-title":"EBioMedicine"},{"key":"91187_CR8","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1111\/bcp.15252","volume":"88","author":"S Imai","year":"2022","unstructured":"Imai, S. et al. Using Japanese big data to investigate novel factors and their high-risk combinations that affect vancomycin-induced nephrotoxicity. Br. J. Clin. Pharmacol. 88, 3241\u20133255 (2022).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"91187_CR9","doi-asserted-by":"publisher","first-page":"112744","DOI":"10.1016\/j.biopha.2022.112744","volume":"148","author":"Y Zamami","year":"2022","unstructured":"Zamami, Y. et al. Identification of prophylactic drugs for oxaliplatin-induced peripheral neuropathy using big data. Biomed. Pharmacother. 148, 112744 (2022).","journal-title":"Biomed. Pharmacother"},{"key":"91187_CR10","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1136\/jamia.2010.008607","volume":"17","author":"PM Nadkarni","year":"2010","unstructured":"Nadkarni, P. M. Drug safety surveillance using de-identified EMR and claims data: issues and challenges. J. Am. Med. Inf. Assoc. 17, 671\u2013674 (2010).","journal-title":"J. Am. Med. Inf. Assoc."},{"key":"91187_CR11","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1377\/hlthaff.2011.0190","volume":"30","author":"DC Classen","year":"2011","unstructured":"Classen, D. C. et al. Global trigger tool\u2019 shows that adverse events in hospitals May be ten times greater than previously measured. Health Aff. (Millwood). 30, 581\u2013589 (2011).","journal-title":"Health Aff (Millwood)"},{"key":"91187_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41698-023-00383-y","volume":"7","author":"R Perez-Lopez","year":"2023","unstructured":"Perez-Lopez, R., Reis-Filho, J. S. & Kather, J. N. A framework for artificial intelligence in cancer research and precision oncology. NPJ Precis. Oncol. 7, 43 (2023).","journal-title":"NPJ Precis Oncol."},{"key":"91187_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41746-022-00590-0","volume":"5","author":"S Khurshid","year":"2022","unstructured":"Khurshid, S. et al. Cohort design and natural Language processing to reduce bias in electronic health records research. NPJ Digit. Med. 5, 47 (2022).","journal-title":"NPJ Digit. Med."},{"key":"91187_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41746-023-00970-0","volume":"7","author":"M Guevara","year":"2024","unstructured":"Guevara, M. et al. Large Language models to identify social determinants of health in electronic health records. NPJ Digit. Med. 7, 6 (2024).","journal-title":"NPJ Digit. Med."},{"key":"91187_CR15","unstructured":"Vaswani, A. et al. Attention is all you need. ArXiv (2017)."},{"key":"91187_CR16","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.1810.04805","author":"J Devlin","year":"2018","unstructured":"Devlin, J., Chang, M., Lee, K. & Toutanova, K. Pre-training of deep bidirectional Transformers for Language Understanding. ArXiv. https:\/\/doi.org\/10.48550\/arXiv.1810.04805 (2018).","journal-title":"ArXiv"},{"key":"91187_CR17","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1093\/bioinformatics\/btz682","volume":"36","author":"J Lee","year":"2020","unstructured":"Lee, J. et al. BioBERT: a pre-trained biomedical Language representation model for biomedical text mining. Bioinformatics 36, 1234\u20131240 (2020).","journal-title":"Bioinformatics"},{"key":"91187_CR18","doi-asserted-by":"publisher","first-page":"e0259763","DOI":"10.1371\/journal.pone.0259763","volume":"16","author":"Y Kawazoe","year":"2021","unstructured":"Kawazoe, Y., Shibata, D., Shinohara, E., Aramaki, E. & Ohe, K. A clinical specific BERT developed using a huge Japanese clinical text corpus. PLoS One. 16, e0259763 (2021).","journal-title":"PLoS One"},{"key":"91187_CR19","doi-asserted-by":"publisher","first-page":"13847","DOI":"10.1038\/s41598-022-17806-8","volume":"12","author":"Y Kim","year":"2022","unstructured":"Kim, Y. et al. A pre-trained BERT for Korean medical natural Language processing. Sci. Rep. 12, 13847 (2022).","journal-title":"Sci. Rep."},{"key":"91187_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12911-018-0687-6","volume":"18","author":"S Zhou","year":"2018","unstructured":"Zhou, S., Kang, H., Yao, B. & Gong, Y. An automated pipeline for analyzing medication event reports in clinical settings. BMC Med. Inf. Decis. Mak. 18, 113 (2018).","journal-title":"BMC Med. Inf. Decis. Mak."},{"key":"91187_CR21","doi-asserted-by":"publisher","first-page":"102473","DOI":"10.1016\/j.ipm.2020.102473","volume":"58","author":"E El-allaly","year":"2021","unstructured":"El-allaly, E., Sarrouti, M. & En-Nahnahi, N. Ouatik El Alaoui S. MTTLADE: A multi-task transfer learning-based method for adverse drug events extraction. Inf. Process. Manag. 58, 102473 (2021).","journal-title":"Inf. Process. Manag"},{"key":"91187_CR22","first-page":"420","volume":"2021","author":"D Mahendran","year":"2021","unstructured":"Mahendran, D. & McInnes, B. T Extracting adverse drug events from clinical notes. AMIA Jt. Summits Transl. Sci. Proc. 2021, 420\u2013429 (2021).","journal-title":"AMIA Jt. Summits Transl Sci. Proc."},{"key":"91187_CR23","doi-asserted-by":"publisher","first-page":"e26407","DOI":"10.2196\/26407","volume":"9","author":"H Wu","year":"2021","unstructured":"Wu, H. et al. Chinese-named entity recognition from adverse drug event records: radical embedding-combined dynamic embedding-based BERT in a bidirectional long short-term conditional random field (Bi-LSTM-CRF) model. JMIR Med. Inf. 9, e26407 (2021).","journal-title":"JMIR Med. Inf."},{"key":"91187_CR24","doi-asserted-by":"publisher","first-page":"103960","DOI":"10.1016\/j.jbi.2021.103960","volume":"125","author":"S Narayanan","year":"2022","unstructured":"Narayanan, S. et al. A contextual multi-task neural approach to medication and adverse events identification from clinical text. J. Biomed. Inf. 125, 103960 (2022).","journal-title":"J. Biomed. Inf."},{"key":"91187_CR25","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s40264-023-01323-2","volume":"46","author":"S Kim","year":"2023","unstructured":"Kim, S. et al. Automatic extraction of comprehensive drug safety information from adverse drug event narratives in the Korea adverse event reporting system using natural Language processing techniques. Drug Saf. 46, 781\u2013795 (2023).","journal-title":"Drug Saf."},{"key":"91187_CR26","doi-asserted-by":"publisher","first-page":"1058435","DOI":"10.3389\/fragi.2022.1058435","volume":"3","author":"LK Booth","year":"2022","unstructured":"Booth, L. K., Redgrave, R. E., Folaranmi, O., Gill, J. H. & Richardson, G. D. Anthracycline-induced cardiotoxicity and senescence. Front. Aging. 3, 1058435 (2022).","journal-title":"Front. Aging"},{"key":"91187_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41698-017-0034-x","volume":"1","author":"X Han","year":"2017","unstructured":"Han, X., Zhou, Y. & Liu, W. Precision cardio-oncology: Understanding the cardiotoxicity of cancer therapy. NPJ Precis. Oncol. 1, 31 (2017).","journal-title":"NPJ Precis Oncol."},{"key":"91187_CR28","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s10741-023-10328-z","volume":"28","author":"Y Gao","year":"2023","unstructured":"Gao, Y. et al. ACEI\/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: a systematic review and meta-analysis. Heart Fail. Rev. 28, 1405\u20131415 (2023).","journal-title":"Heart Fail. Rev."},{"key":"91187_CR29","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1093\/eurheartj\/ehab843","volume":"43","author":"C Lewinter","year":"2022","unstructured":"Lewinter, C. et al. A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer. Eur. Heart J. 43, 2562\u20132569 (2022).","journal-title":"Eur. Heart J."},{"key":"91187_CR30","doi-asserted-by":"publisher","first-page":"7034","DOI":"10.21037\/tcr-20-1869","volume":"9","author":"H Dong","year":"2020","unstructured":"Dong, H. et al. Can ACEI\/ARB prevent the cardiotoxicity caused by chemotherapy in early-stage breast cancer? -a meta-analysis of randomized controlled trials. Transl. Cancer Res. 9, 7034\u20137043 (2020).","journal-title":"Transl Cancer Res."},{"key":"91187_CR31","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1016\/j.ejca.2013.04.030","volume":"49","author":"K Kalam","year":"2013","unstructured":"Kalam, K. & Marwick, T. H. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur. J. Cancer. 49, 2900\u20132909 (2013).","journal-title":"Eur. J. Cancer"},{"key":"91187_CR32","first-page":"10","volume":"9","author":"A Mir","year":"2023","unstructured":"Mir, A. et al. Efficacy and safety of cardioprotective drugs in chemotherapy-induced cardiotoxicity: an updated systematic review & network meta-analysis. Cardiooncology 9, 10 (2023).","journal-title":"Cardiooncology"},{"key":"91187_CR33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40360-019-0298-6","volume":"20","author":"Y Ma","year":"2019","unstructured":"Ma, Y. et al. Beta-blockers for the primary prevention of anthracycline-induced cardiotoxicity: a meta-analysis of randomized controlled trials. BMC Pharmacol. Toxicol. 20, 18 (2019).","journal-title":"BMC Pharmacol. Toxicol."},{"key":"91187_CR34","doi-asserted-by":"publisher","first-page":"968534","DOI":"10.3389\/fcvm.2022.968534","volume":"9","author":"D He","year":"2022","unstructured":"He, D., Hu, J., Li, Y. & Zeng, X. Preventive use of beta-blockers for anthracycline-induced cardiotoxicity: A network meta-analysis. Front. Cardiovasc. Med. 9, 968534 (2022).","journal-title":"Front. Cardiovasc. Med."},{"key":"91187_CR35","doi-asserted-by":"publisher","first-page":"101885","DOI":"10.1016\/j.cpcardiol.2023.101885","volume":"48","author":"A Titus","year":"2023","unstructured":"Titus, A. et al. Statin for attenuating cardiotoxicity in patients receiving anthracyclines: a systematic review and meta-analysis. Curr. Probl. Cardiol. 48, 101885 (2023).","journal-title":"Curr. Probl. Cardiol."},{"key":"91187_CR36","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1177\/1074248418821721","volume":"24","author":"M Nabati","year":"2019","unstructured":"Nabati, M., Janbabai, G., Esmailian, J. & Yazdani, J. Effect of Rosuvastatin in preventing chemotherapy-induced cardiotoxicity in women with breast cancer: a randomized, single-blind, placebo-controlled trial. J. Cardiovasc. Pharmacol. Ther. 24, 233\u2013241 (2019).","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"91187_CR37","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1001\/jama.2023.11887","volume":"330","author":"TG Neilan","year":"2023","unstructured":"Neilan, T. G. et al. Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial. JAMA 330, 528\u2013536 (2023).","journal-title":"JAMA"},{"key":"91187_CR38","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/ehjcvp\/pvad031","volume":"9","author":"P Thavendiranathan","year":"2023","unstructured":"Thavendiranathan, P. et al. Statin to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines. Eur. Heart J. Cardiovasc. Pharmacother. 9, 515\u2013525 (2023).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother"},{"key":"91187_CR39","doi-asserted-by":"publisher","unstructured":"Hundley, W. G. et al. Statin and left ventricular ejection fraction following doxorubicin treatment. NEJM Evid. https:\/\/doi.org\/10.1056\/evidoa2200097 (2022).","DOI":"10.1056\/evidoa2200097"},{"key":"91187_CR40","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/ejhf.196","volume":"17","author":"M Akpek","year":"2015","unstructured":"Akpek, M. et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur. J. Heart Fail. 17, 81\u201389 (2015).","journal-title":"Eur. J. Heart Fail."},{"key":"91187_CR41","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1089\/cdd.1987.4.129","volume":"4","author":"J Milei","year":"1987","unstructured":"Milei, J., Marantz, A., Al\u00e9, J., Vazquez, A. & Buceta, J. E. Prevention of adriamycin-induced cardiotoxicity by prenylamine: a pilot double blind study. Cancer Drug Deliv. 4, 129\u2013136 (1987).","journal-title":"Cancer Drug Deliv"},{"key":"91187_CR42","first-page":"566","volume":"33","author":"J Kraft","year":"1990","unstructured":"Kraft, J. et al. Effects of verapamil on anthracycline-induced cardiomyopathy: preliminary results of a prospective multicenter trial. Haematol. Blood Transfus. 33, 566\u2013570 (1990).","journal-title":"Haematol. Blood Transfus."},{"key":"91187_CR43","first-page":"18","volume":"5","author":"N Bansal","year":"2019","unstructured":"Bansal, N. et al. Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Cardiooncology 5, 18 (2019).","journal-title":"Cardiooncology"},{"key":"91187_CR44","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41440-019-0238-2","volume":"42","author":"M Ohishi","year":"2019","unstructured":"Ohishi, M. et al. Analysis of antihypertensive treatment using real-world Japanese data-the retrospective study of antihypertensives for Lowering blood pressure (REAL) study. Hypertens. Res. 42, 1057\u20131067 (2019).","journal-title":"Hypertens. Res."},{"key":"91187_CR45","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/10641963.2018.1465074","volume":"41","author":"T Ishida","year":"2019","unstructured":"Ishida, T., Oh, A., Hiroi, S., Shimasaki, Y. & Tsuchihashi, T. Current prescription status of antihypertensive drugs in Japanese patients with hypertension: analysis by type of comorbidities. Clin. Exp. Hypertens. 41, 203\u2013210 (2019).","journal-title":"Clin. Exp. Hypertens."},{"key":"91187_CR46","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0031-6989(88)80012-2","volume":"20","author":"E Monti","year":"1988","unstructured":"Monti, E., Paracchini, L., Piccinini, F., Rozza, A. & Villani, F. Effect of calcium inhibitors and calcium mobilizers on doxorubicin accumulation in rat myocardial tissue. Pharmacol. Res. Commun. 20, 369\u2013376 (1988).","journal-title":"Pharmacol. Res. Commun."},{"key":"91187_CR47","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/0041-008X(91)90277-L","volume":"108","author":"G Santostasi","year":"1991","unstructured":"Santostasi, G., Kutty, R. K. & Krishna, G. Increased toxicity of anthracycline antibiotics induced by calcium entry blockers in cultured cardiomyocytes. Toxicol. Appl. Pharmacol. 108, 140\u2013149 (1991).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"91187_CR48","doi-asserted-by":"publisher","first-page":"ooad111","DOI":"10.1093\/jamiaopen\/ooad111","volume":"6","author":"Z Lan","year":"2023","unstructured":"Lan, Z. & Turchin, A. Impact of possible errors in natural Language processing-derived data on downstream epidemiologic analysis. JAMIA Open. 6, ooad111 (2023).","journal-title":"JAMIA Open."},{"key":"91187_CR49","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli, M. et al. The reporting of A disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): explanation and elaboration. Drug Saf. 47, 585\u2013599 (2024).","journal-title":"Drug Saf."},{"key":"91187_CR50","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMp0905338","volume":"361","author":"R Platt","year":"2009","unstructured":"Platt, R. et al. The new Sentinel Network\u2013improving the evidence of medical-product safety. N. Engl. J. Med. 361, 645\u2013647 (2009).","journal-title":"N Engl. J. Med."},{"key":"91187_CR51","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1002\/pds.4879","volume":"28","author":"M Yamaguchi","year":"2019","unstructured":"Yamaguchi, M. et al. Establishment of the MID-NET\u00ae medical information database network as a reliable and valuable database for drug safety assessments in Japan. Pharmacoepidemiol. Drug Saf. 28, 1395\u20131404 (2019).","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"91187_CR52","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41586-023-06291-2","volume":"620","author":"K Singhal","year":"2023","unstructured":"Singhal, K. et al. Large Language models encode clinical knowledge. Nature 620, 172\u2013180 (2023).","journal-title":"Nature"},{"key":"91187_CR53","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1536\/ihj.46.855","volume":"46","author":"H Yasunaga","year":"2005","unstructured":"Yasunaga, H., Ide, H., Imamura, T. & Ohe, K. Impact of the Japanese diagnosis procedure combination-based payment system on cardiovascular medicine-related costs. Int. Heart J. 46, 855\u2013866 (2005).","journal-title":"Int. Heart J."},{"key":"91187_CR54","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.je.2016.09.009","volume":"27","author":"H Yamana","year":"2017","unstructured":"Yamana, H. et al. Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. J. Epidemiol. 27, 476\u2013482 (2017).","journal-title":"J. Epidemiol."},{"key":"91187_CR55","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/00031305.1985.10479383","volume":"39","author":"PR Rosenbaum","year":"1985","unstructured":"Rosenbaum, P. R. & Rubin, D. B. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am. Stat. 39, 33\u201338 (1985).","journal-title":"Am. Stat."},{"key":"91187_CR56","doi-asserted-by":"crossref","unstructured":"Yada, S., Nakamura, Y., Wakamiya, S. & Aramaki, E. Cross-lingual natural Language processing on limited annotated case\/radiology reports in english and Japanese: insights from the Real-MedNLP workshop. Methods Inf. Med. (2024).","DOI":"10.1055\/a-2405-2489"},{"key":"91187_CR57","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/rssb.12027","volume":"76","author":"K Imai","year":"2014","unstructured":"Imai, K. & Ratkovic, M. Covariate balancing propensity score. J. R. Stat. Soc. Ser. B Stat. Methodol. 76, 243\u2013263 (2014).","journal-title":"J. R Stat. Soc. Ser. B Stat. Methodol."},{"key":"91187_CR58","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1093\/aje\/kwu181","volume":"180","author":"R Wyss","year":"2014","unstructured":"Wyss, R. et al. The role of prediction modeling in propensity score estimation: an evaluation of logistic regression, bCART, and the covariate-balancing propensity score. Am. J. Epidemiol. 180, 645\u2013655 (2014).","journal-title":"Am. J. Epidemiol."},{"key":"91187_CR59","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin, P. C. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat. Med. 28, 3083\u20133107 (2009).","journal-title":"Stat. Med."},{"key":"91187_CR60","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12874-017-0338-0","volume":"17","author":"TL Nguyen","year":"2017","unstructured":"Nguyen, T. L. et al. Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance. BMC Med. Res. Methodol. 17, 78 (2017).","journal-title":"BMC Med. Res. Methodol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91187-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91187-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91187-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T12:57:25Z","timestamp":1740401845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91187-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["91187"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-91187-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4989886\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]},"assertion":[{"value":"28 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YK, KS, and ES belong to the Artificial Intelligence and Digital Twin in Healthcare, Graduate School of Medicine, University of Tokyo, which is an endowment department supported by an unrestricted grant from EM Systems, EPNextS, MRP Co., Ltd., SHIP HEALTHCARE HOLDINGS, Inc., SoftBank Corp., and NEC Corporation; these organizations had no control over the interpretation, writing, or publication of this work. All authors declare no financial or non-financial competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6678"}}